AU2022204166B2 — 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities
Assigned to Deciphera Pharmaceuticals LLC · Expires 2024-02-15 · 2y expired
What this patent protects
Described are compounds of Formula I x1 0 W N N X2 A N Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-lR), c-KIT, and/or PDGFR kinases. These compounds also find utility in the tre…
USPTO Abstract
Described are compounds of Formula I x1 0 W N N X2 A N Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-lR), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.
Drugs covered by this patent
- Romvimza (VIMSELTINIB) · Deciphera Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.